M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

What’s Hot – BXN, ILT, LRV, EXR, LTP, WTM & PSC

What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – BXN, ILT, LRV, EXR, LTP, WTM & PSC What’s Not – ING What’s Hot BXN – Bioxyne Limited today closed up 71% to finish at 1.2c on $470k stock traded. There was no news out today […]

What’s Hot – FL1, ION, SER, SS1, RDN, VTX, M2R, ERW & LTP

What’s Hot, Not & Doing Brought to you by TSN Contributor & Wealth Advisor Nick Kelso What’s Hot – FL1, ION, SER, SS1, RDN, VTX, M2R, ERW & LTP What’s Not – MP1 What’s Hot FL1 – First Lithium Limited today closed up 65% to finish at 15.5c on $200k stock traded. The reason they […]

HITIQ Limited (ASX:HIQ) secures second US Patent for key part of its Nexus™ technology

HITIQ Limited (ASX:HIQ) has received a second US Patent relating to an innovative design feature for its Nexus™ technology. The US Patent and Trademark Office has issued a Notice of Allowance for HITIQ’s patent application US 17/427,869 “Instrumented mouthguard devices and components configured for use in instrumented mouthguard devices “, meaning that the Company expects […]

Lithium Universe (ASX:LU7): Leverage to rising demand for lithium chemical products

Lithium Universe (ASX:LU7) plans to address the ‘Lithium Conversion Gap’ in North America by developing a process in Canada, to turn mined lithium into battery-grade lithium carbonate. This will allow the company to supply the auto industry with lithium chemicals needed for electric vehicle (EV) batteries. Lithium Universe plans to use”take or pay” contracts with […]

BlinkLab (ASX:BB1): Creating better tests to diagnose various neurodevelopmental conditions

BlinkLab (ASX:BB1) is a digital healthcare company that uses smartphones, computer vision, AI, and machine learning to create a platform for diagnosing neurodevelopmental conditions like autism, ADHD, and schizophrenia. Their most advanced product is an autism diagnostic test for children as young as 18 months old. This test is much better than traditional methods, which […]

EZZ Life Science Holdings (ASX:EZZ) Creating health supplements that meet identified consumer demand

EZZ Life Science Holdings (ASX:EZZ) is a life science company focussed on genomic research and development, addressing four key human health challenges: genetic longevity, human papillomavirus (HPV), children’s care, and weight management. The Company formulates, produces and distributes health supplements under the brand of EZZ, and is also an exclusive distributor of skin care products. […]

FBR Limited (ASX:FBR): Brick laying robot systems developer revolutionising building construction

FBR Limited (ASX:FBR) designs, develops and builds dynamically stabilised robots. These robots are designed to work outdoors and use the Company’s proprietary core Dynamic Stabilisation Technology® platform, or DST® for short. The first application of DST® is Hadrian X®, a bricklaying robot that builds structural walls faster, safer, more accurately and with less wastage than […]

PharmAust Limited (ASX:PAA): Developing new treatments for neurodegenerative diseases

PharmAust ASX:PAA) is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel for amyotrophic lateral sclerosis, the most common form of motor neurone disease. It has recently realised significant milestones in the development of monepantel for this sclerosis. These achievements include a recent study that could potentially lead […]